Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Summary by Enid News & Eagle
MARSEILLE, France--(BUSINESS WIRE)--Jul 21, 2026-

4 Articles

Hastings TribuneHastings Tribune
+3 Reposted by 3 other sources
Center

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

MARSEILLE, France--(BUSINESS WIRE)--Jul 21, 2026-

·Nebraska, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

innate-pharma.com broke the news on Monday, July 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Marseille icon

Marseille

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal